

USA, SEER 18, Native American (1993-2012)

	Number of cases							Percentage				Incidence rates per million person-years							MV % 0-19	DCO % 0-19			
	Age group							0-14		0-19		Age-specific					Cumulative						
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR			0-19	0-14	0-19
I LEUKAEMIA	12	78	45	46	41	181	222	38.4	100.0	33.3	100.0	34.6	55.3	24.6	24.1	21.6	34.7	31.8	499	607	95.9	0.5	
a. Lymphoid	7	63	30	26	15	126	141	26.8	69.6	21.1	63.5	20.2	44.7	16.4	13.6	7.9	24.7	20.9	349	389	95.7	0.7	
b. Acute myeloid	3	9	9	14	15	35	50	7.4	19.3	7.5	22.5	8.7	6.4	4.9	7.3	7.9	6.4	6.7	95	135	100.0	0.0	
c. CMD	1	1	0	2	7	4	11	0.8	2.2	1.6	5.0	2.9	0.7	-	1.0	3.7	0.7	1.4	11	29	100.0	0.0	
d. MDS & other	1	2	4	2	3	9	12	1.9	5.0	1.8	5.4	2.9	1.4	2.2	1.0	1.6	1.7	1.7	25	33	91.7	0.0	
e. Unspecified	0	3	2	2	1	7	8	1.5	3.9	1.2	3.6	-	2.1	1.1	1.0	0.5	1.3	1.1	19	22	75.0	0.0	
II LYMPHOMA & RELATED	5	10	9	15	29	39	68	8.3	100.0	10.2	100.0	14.4	7.1	4.9	7.8	15.3	7.2	9.0	107	183	97.1	0.0	
a. Hodgkin	0	1	2	6	13	9	22	1.9	23.1	3.3	32.4	-	0.7	1.1	3.1	6.9	1.5	2.7	24	58	100.0	0.0	
b. Non-Hodgkin except BL	0	3	5	8	13	16	29	3.4	41.0	4.3	42.6	-	2.1	2.7	4.2	6.9	2.8	3.7	43	77	96.6	0.0	
c. Burkitt (BL)	0	2	0	1	3	3	6	0.6	7.7	0.9	8.8	-	1.4	-	0.5	1.6	0.6	0.8	8	16	100.0	0.0	
d. Lymphoreticular	4	4	2	0	0	10	10	2.1	25.6	1.5	14.7	11.5	2.8	1.1	-	-	2.1	1.6	28	28	90.0	0.0	
e. Unspecified	1	0	0	0	0	1	1	0.2	2.6	0.1	1.5	2.9	-	-	-	-	0.2	0.2	3	3	100.0	0.0	
III CNS NEOPLASMS	4	24	25	18	21	71	92	15.1	100.0	13.8	100.0	11.5	17.0	13.7	9.4	11.1	13.3	12.8	195	250	83.7	0.0	
a. Ependymoma	1	1	2	1	1	5	6	1.1	7.0	0.9	6.5	2.9	0.7	1.1	0.5	0.5	0.9	0.9	14	16	100.0	0.0	
b. Astrocytoma	1	10	8	10	11	29	40	6.2	40.8	6.0	43.5	2.9	7.1	4.4	5.2	5.8	5.4	5.5	79	108	77.5	0.0	
c. CNS embryonal	1	9	9	2	3	21	24	4.5	29.6	3.6	26.1	2.9	6.4	4.9	1.0	1.6	4.1	3.5	58	66	100.0	0.0	
d. Other gliomas	0	2	5	3	6	10	16	2.1	14.1	2.4	17.4	-	1.4	2.7	1.6	3.2	1.8	2.1	27	43	68.8	0.0	
e. Other specified	1	1	1	1	0	4	4	0.8	5.6	0.6	4.3	2.9	0.7	0.5	0.5	-	0.8	0.6	11	11	100.0	0.0	
f. Unspecified CNS	0	1	0	1	0	2	2	0.4	2.8	0.3	2.2	-	0.7	-	0.5	-	0.4	0.3	5	5	50.0	0.0	
IV NEUROBLASTOMA	12	9	0	2	2	23	25	4.9	100.0	3.7	100.0	34.6	6.4	-	1.0	1.1	4.9	4.1	65	70	100.0	0.0	
a. (Ganglio)neuroblastoma	12	9	0	1	1	22	23	4.7	95.7	3.4	92.0	34.6	6.4	-	0.5	0.5	4.8	3.8	62	65	100.0	0.0	
b. Peripheral nervous	0	0	0	1	1	1	2	0.2	4.3	0.3	8.0	-	-	-	0.5	0.5	0.2	0.2	3	5	100.0	0.0	
V RETINOBLASTOMA	9	10	2	0	0	21	21	4.5	100.0	3.1	100.0	26.0	7.1	1.1	-	-	4.5	3.5	60	60	81.0	0.0	
VI RENAL TUMOURS	6	19	5	1	2	31	33	6.6	100.0	4.9	100.0	17.3	13.5	2.7	0.5	1.1	6.5	5.3	87	93	100.0	0.0	
a. Nephroblastoma	6	18	5	0	0	29	29	6.2	93.5	4.3	87.9	17.3	12.8	2.7	-	-	6.2	4.8	82	82	100.0	0.0	
b. Renal carcinoma	0	1	0	1	2	2	4	0.4	6.5	0.6	12.1	-	0.7	-	0.5	1.1	0.4	0.5	5	11	100.0	0.0	
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VII HEPATIC TUMOURS	5	11	2	2	3	20	23	4.2	100.0	3.4	100.0	14.4	7.8	1.1	1.0	1.6	4.2	3.6	56	64	95.7	0.0	
a. Hepatoblastoma	5	11	1	0	0	17	17	3.6	85.0	2.5	73.9	14.4	7.8	0.5	-	-	3.7	2.9	48	48	94.1	0.0	
b. Hepatic carcinoma	0	0	1	2	3	3	6	0.6	15.0	0.9	26.1	-	-	0.5	1.0	1.6	0.5	0.7	8	16	100.0	0.0	
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VIII BONE TUMOURS	0	2	7	18	9	27	36	5.7	100.0	5.4	100.0	-	1.4	3.8	9.4	4.7	4.4	4.5	72	96	97.2	0.0	
a. Osteosarcoma	0	0	2	11	4	13	17	2.8	48.1	2.5	47.2	-	-	1.1	5.8	2.1	2.0	2.0	34	45	100.0	0.0	
b. Chondrosarcoma	0	0	0	0	1	0	1	-	-	0.1	2.8	-	-	-	-	0.5	-	0.1	-	3	3	100.0	0.0
c. Ewing & related	0	1	3	6	3	10	13	2.1	37.0	1.9	36.1	-	0.7	1.6	3.1	1.6	1.7	1.6	27	35	100.0	0.0	
d. Other specified	0	0	1	1	1	2	3	0.4	7.4	0.4	8.3	-	-	0.5	0.5	0.5	0.3	0.4	5	8	100.0	0.0	
e. Unspecified	0	1	1	0	0	2	2	0.4	7.4	0.3	5.6	-	0.7	0.5	-	-	0.4	0.3	6	6	50.0	0.0	
IX SOFT TISSUE SARCOMA	4	14	2	11	24	31	55	6.6	100.0	8.2	100.0	11.5	9.9	1.1	5.8	12.6	6.0	7.5	85	149	100.0	0.0	
a. Rhabdomyosarcoma	2	10	1	3	5	16	21	3.4	51.6	3.1	38.2	5.8	7.1	0.5	1.6	2.6	3.3	3.1	45	58	100.0	0.0	
b. Fibrosarcoma	2	0	0	0	1	2	3	0.4	6.5	0.4	5.5	5.8	-	-	-	0.5	0.4	0.5	6	8	100.0	0.0	
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
d. Other specified	0	4	1	7	16	12	28	2.5	38.7	4.2	50.9	-	2.8	0.5	3.7	8.4	2.1	3.5	32	75	100.0	0.0	
e. Unspecified	0	0	0	1	2	1	3	0.2	3.2	0.4	5.5	-	-	-	0.5	1.1	0.2	0.4	3	8	100.0	0.0	
X GERM CELL TUMOURS	1	2	0	4	26	7	33	1.5	100.0	4.9	100.0	2.9	1.4	-	2.1	13.7	1.3	4.1	19	88	93.9	0.0	
a. CNS germ cell	0	0	0	1	0	1	1	0.2	14.3	0.1	3.0	-	-	-	0.5	-	0.2	0.1	3	3	100.0	0.0	
b. Other extragonadal	0	1	0	0	2	1	3	0.2	14.3	0.4	9.1	-	0.7	-	-	1.1	0.2	0.4	3	8	66.7	0.0	
c. Gonadal germ cell	1	1	0	3	23	5	28	1.1	71.4	4.2	84.8	2.9	0.7	-	1.6	12.1	0.9	3.4	14	74	96.4	0.0	
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	-	0.1	3.0	-	-	-	-	0.5	-	0.1	-	3	3	100.0	0.0
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
XI CARCINOMA & MELANOMA	0	0	7	11	38	18	56	3.8	100.0	8.4	100.0	-	-	3.8	5.8	20.0	2.9	6.8	48	148	100.0	0.0	
a. Adrenocortical	0	0	1	1	0	2	2	0.4	11.1	0.3	3.6	-	-	0.5	0.5	-	0.3	0.3	5	5	100.0	0.0	
b. Thyroid	0	0	2	5	20	7	27	1.5	38.9	4.0	48.2	-	-	1.1	2.6	10.5	1.1	3.2	19	71	100.0	0.0	
c. Nasopharyngeal	0	0	0	1	1	1	2	0.2	5.6	0.3	3.6	-	-	-	0.5	0.5	0.2	0.2	3	5	100.0	0.0	
d. Melanoma	0	0	2	3	1	5	6	1.1	27.8	0.9	10.7	-	-	1.1	1.6	0.5	0.8	0.7	13	16	100.0	0.0	
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
f. Other & unspecified	0	0	2	1	16	3	19	0.6	16.7	2.8	33.9	-	-	1.1	0.5	8.4	0.5	2.3	8	50	100.0	0.0	
XII OTHER & UNSPECIFIED	0	1	0	1	1	2	3	0.4	100.0	0.4	100.0	-	0.7	-	0.5	0.5	0.4	0.4	5	8	33.3	0.0	
a. Other specified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
b. Other unspecified	0	1	0	1	1	2	3	0.4	100.0	0.4	100.0	-	0.7	-	0.5	0.5	0.4	0.4	5	8	33.3	0.0	
TOTAL	58	180	104	129	196	471	667	100.0	100.0	100.0	100.0	167.3	127.6	56.9	67.5	103.3	90.4	93.3	1299	1815	94.6	0.1	

Please consult the quality indicators for the constituent registries

USA, SEER 18, Native American (1993-2012)

	Males										M/F ratio		Females									
	Number of cases in age groups					ASR per million					0-14	0-19	Number of cases in age groups					ASR per million				
	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19	0			1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19		
I LEUKAEMIA	8	45	24	27	19	104	123	39.4	35.0	1.4	1.2	4	33	21	19	22	77	99	29.9	28.5		
a. Lymphoid	4	37	18	18	10	77	87	29.5	25.1	1.6	1.6	3	26	12	8	5	49	54	19.7	16.5		
b. Acute myeloid	3	5	4	5	6	17	23	6.4	6.3	0.9	0.9	0	4	5	9	9	18	27	6.3	7.1		
c. CMD	0	1	0	2	1	3	4	1.0	1.0	3.0	0.6	1	0	0	0	6	1	7	0.4	1.8		
d. MDS & other	1	0	2	1	1	4	5	1.4	1.3	0.8	0.7	0	2	2	1	2	5	7	1.9	2.0		
e. Unspecified	0	2	0	1	1	3	4	1.2	1.1	0.8	1.0	0	1	2	1	0	4	4	1.5	1.1		
II LYMPHOMA & RELATED	2	7	4	13	13	26	39	9.2	10.1	2.0	1.3	3	3	5	2	16	13	29	5.1	7.8		
a. Hodgkin	0	1	1	6	4	8	12	2.6	2.9	8.0	1.2	0	0	1	0	9	1	10	0.4	2.5		
b. Non-Hodgkin except BL	0	2	2	6	7	10	17	3.4	4.2	1.7	1.4	0	1	3	2	6	6	12	2.1	3.1		
c. Burkitt (BL)	0	2	0	1	2	3	5	1.2	1.4	-	5.0	0	0	0	0	1	0	1	-	0.2		
d. Lymphoreticular	1	2	1	0	0	4	4	1.6	1.3	0.7	0.7	3	2	1	0	0	6	6	2.6	2.0		
e. Unspecified	1	0	0	0	0	1	1	0.4	0.3	-	-	0	0	0	0	0	0	0	-	-		
III CNS NEOPLASMS	3	12	15	9	9	39	48	14.4	13.3	1.2	1.1	1	12	10	9	12	32	44	12.2	12.3		
a. Ependymoma	1	1	1	1	0	4	4	1.5	1.2	4.0	2.0	0	0	1	0	1	1	2	0.4	0.5		
b. Astrocytoma	0	4	6	4	5	14	19	5.0	5.0	0.9	0.9	1	6	2	6	6	15	21	5.7	5.9		
c. CNS embryonal	1	5	5	1	2	12	14	4.6	4.1	1.3	1.4	0	4	4	1	1	9	10	3.5	3.0		
d. Other gliomas	0	1	2	2	2	5	7	1.7	1.8	1.0	0.8	0	1	3	1	4	5	9	1.8	2.4		
e. Other specified	1	0	1	1	0	3	3	1.1	0.8	3.0	3.0	0	1	0	0	0	1	1	0.4	0.3		
f. Unspecified CNS	0	1	0	0	0	1	1	0.4	0.3	1.0	1.0	0	0	0	1	0	1	1	0.3	0.2		
IV NEUROBLASTOMA	3	5	0	0	2	8	10	3.5	3.2	0.5	0.7	9	4	0	2	0	15	15	6.4	5.0		
a. (Ganglio)neuroblastoma	3	5	0	0	1	8	9	3.5	2.9	0.6	0.6	9	4	0	1	0	14	14	6.1	4.7		
b. Peripheral nervous	0	0	0	0	1	0	1	-	0.2	0.0	1.0	0	0	0	1	0	1	1	0.3	0.2		
V RETINOBLASTOMA	7	6	2	0	0	15	15	6.3	4.9	2.5	2.5	2	4	0	0	0	6	6	2.7	2.1		
VI RENAL TUMOURS	3	6	3	1	0	13	13	5.2	4.1	0.7	0.7	3	13	2	0	2	18	20	7.9	6.6		
a. Nephroblastoma	3	6	3	0	0	12	12	4.9	3.8	0.7	0.7	3	12	2	0	0	17	17	7.4	5.8		
b. Renal carcinoma	0	0	0	1	0	1	1	0.3	0.2	1.0	0.3	0	1	0	0	2	1	3	0.4	0.8		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
VII HEPATIC TUMOURS	4	9	1	2	2	16	18	6.6	5.6	4.0	3.6	1	2	1	0	1	4	5	1.7	1.6		
a. Hepatoblastoma	4	9	0	0	0	13	13	5.6	4.4	3.3	3.3	1	2	1	0	0	4	4	1.7	1.3		
b. Hepatic carcinoma	0	0	1	2	2	3	5	0.9	1.2	-	5.0	0	0	0	0	1	0	1	-	0.2		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
VIII BONE TUMOURS	0	2	2	13	5	17	22	5.5	5.4	1.7	1.6	0	0	5	5	4	10	14	3.3	3.6		
a. Osteosarcoma	0	0	0	8	3	8	11	2.4	2.6	1.6	1.8	0	0	2	3	1	5	6	1.6	1.5		
b. Chondrosarcoma	0	0	0	0	1	0	1	-	0.2	-	-	0	0	0	0	0	0	0	-	-		
c. Ewing & related	0	1	1	4	1	6	7	2.0	1.8	1.5	1.2	0	0	2	2	2	4	6	1.3	1.5		
d. Other specified	0	0	1	1	0	2	2	0.6	0.5	-	2.0	0	0	0	0	1	0	1	-	0.2		
e. Unspecified	0	1	0	0	0	1	1	0.4	0.3	1.0	1.0	0	0	1	0	0	1	1	0.4	0.3		
IX SOFT TISSUE SARCOMA	3	7	2	8	15	20	35	7.4	9.2	1.8	1.8	1	7	0	3	9	11	20	4.5	5.7		
a. Rhabdomyosarcoma	2	5	1	3	3	11	14	4.3	4.0	2.2	2.0	0	5	0	0	2	5	7	2.2	2.2		
b. Fibrosarcoma	1	0	0	0	1	1	2	0.4	0.6	1.0	2.0	1	0	0	0	0	1	1	0.4	0.3		
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	0	2	1	4	10	7	17	2.4	4.2	1.4	1.5	0	2	0	3	6	5	11	1.8	2.9		
e. Unspecified	0	0	0	1	1	1	2	0.3	0.5	-	2.0	0	0	0	0	1	0	1	-	0.2		
X GERM CELL TUMOURS	1	1	0	2	18	4	22	1.5	5.3	1.3	2.0	0	1	0	2	8	3	11	1.1	2.8		
a. CNS germ cell	0	0	0	1	0	1	1	0.3	0.2	-	-	0	0	0	0	0	0	0	-	-		
b. Other extragonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	0	1	0	0	2	1	3	0.4	0.8		
c. Gonadal germ cell	1	1	0	1	18	3	21	1.2	5.1	1.5	3.0	0	0	0	2	5	2	7	0.6	1.7		
d. Gonadal carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.2		
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
XI CARCINOMA & MELANOMA	0	0	3	6	9	9	18	2.8	4.3	1.0	0.5	0	0	4	5	29	9	38	3.0	9.4		
a. Adrenocortical	0	0	0	1	0	1	1	0.3	0.2	1.0	1.0	0	0	1	0	0	1	1	0.4	0.3		
b. Thyroid	0	0	1	2	2	3	5	0.9	1.2	0.8	0.2	0	0	1	3	18	4	22	1.3	5.4		
c. Nasopharyngeal	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	1	1	2	0.3	0.5		
d. Melanoma	0	0	0	2	0	2	2	0.6	0.5	0.7	0.5	0	0	2	1	1	3	4	1.0	1.0		
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
f. Other & unspecified	0	0	2	1	7	3	10	1.0	2.4	-	1.1	0	0	0	0	9	0	9	-	2.2		
XII OTHER & UNSPECIFIED	0	0	0	1	0	1	1	0.3	0.2	1.0	0.5	0	1	0	0	1	1	2	0.4	0.6		
a. Other specified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
b. Other unspecified	0	0	0	1	0	1	1	0.3	0.2	1.0	0.5	0	1	0	0	1	1	2	0.4	0.6		
TOTAL	34	100	56	82	92	272	364	102.2	100.5	1.4	1.2	24	80	48	47	104	199	303	78.2	85.9		

Please consult the quality indicators for the constituent registries

USA, SEER 18, Native American (1993-2012)

	Age group	Males	Females
Person-years	0	175 516	171 270
	1-4	716 311	694 106
	5-9	928 750	900 275
	10-14	967 128	944 805
	15-19	972 133	925 210
Total	0-14	2 787 705	2 710 456
	0-19	3 759 838	3 635 666
Average annual population	0-14	139 385	135 523
	0-19	187 992	181 783

Please consult the quality indicators for the constituent registries

USA, SEER 18, Native American (1993-2012)

Registry	Period	Cases	%	Person-years	%
Alaska Natives	1993-2012	159	23.8	912 127	12.3
California, Greater California	2000-2012	142	21.3	1 850 981	25.0
California, Los Angeles	1993-2012	10	1.5	856 552	11.6
California, San Francisco	1993-2012	10	1.5	237 220	3.2
California, San José	1993-2012	3	0.4	234 496	3.2
Connecticut	1993-2012	4	0.6	99 137	1.3
Georgia, Atlanta	1993-2012	7	1.0	90 819	1.2
Georgia, Greater Georgia	2000-2012	3	0.4	106 008	1.4
Georgia, Rural	1993-2012	0	0.0	1 482	0.0
Hawaii	1993-2012	5	0.7	29 393	0.4
Iowa	1993-2012	10	1.5	92 739	1.3
Kentucky	2000-2012	2	0.3	41 328	0.6
Louisiana	2000-2012	4	0.6	143 611	1.9
Michigan, Detroit	1993-2012	8	1.2	126 380	1.7
New Jersey	2000-2012	5	0.7	191 327	2.6
New Mexico	1993-2012	182	27.3	1 520 851	20.6
Utah	1993-2012	29	4.3	317 292	4.3
Washington, Seattle	1993-2012	84	12.6	543 761	7.4
USA	1993-2012	667	100.0	7 395 504	100.0

Please consult the quality indicators for the constituent registries

Alaska Natives, Native American
(1993-2012)New Mexico, Native American
(1993-2012)

	Alaska Natives, Native American (1993-2012)			New Mexico, Native American (1993-2012)								
	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR
I LEUKAEMIA	50	1.5	77.5	57	1.5	67.3	58	1.8	51.3	72	1.5	48.2
a. Lymphoid	31	1.6	49.7	33	1.8	40.6	41	2.4	37.0	45	2.0	31.1
b. Acute myeloid	11	1.8	15.6	14	1.3	15.2	11	0.8	9.4	17	0.9	10.8
c. CMD	1	.	1.2	1	.	0.9	1	.	1.0	4	1.0	2.6
d. MDS & other	4	1.0	6.2	5	0.7	5.8	2	1.0	1.6	3	2.0	1.8
e. Unspecified	3	0.5	4.8	4	1.0	4.7	3	0.5	2.3	3	0.5	1.8
II LYMPHOMA & RELATED	17	2.4	26.1	25	1.8	28.6	5	1.5	4.1	11	0.8	6.8
a. Hodgkin	2	.	2.9	4	3.0	4.3	2	1.0	1.6	4	0.3	2.4
b. Non-Hodgkin except BL	6	2.0	8.6	11	1.2	11.9	2	.	1.5	5	4.0	2.9
c. Burkitt (BL)	1	.	1.7	2	.	2.3	0	.	.	1	0.0	0.6
d. Lymphoreticular	7	1.3	11.2	7	1.3	8.7	1	0.0	1.0	1	0.0	0.8
e. Unspecified	1	.	1.7	1	.	1.3	0	.	.	0	.	.
III CNS NEOPLASMS	14	0.8	20.8	18	0.6	20.3	13	0.9	11.2	19	0.9	12.3
a. Ependymoma	2	.	3.4	2	.	2.6	1	.	0.9	2	1.0	1.3
b. Astrocytoma	6	0.5	8.6	9	0.5	9.8	4	3.0	3.2	7	2.5	4.3
c. CNS embryonal	3	2.0	4.3	3	2.0	3.3	6	0.5	5.5	7	0.8	4.9
d. Other gliomas	3	0.0	4.5	4	0.0	4.5	2	0.0	1.6	3	0.0	1.8
e. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
f. Unspecified CNS	0	.	.	0	.	.	0	.	.	0	.	.
IV NEUROBLASTOMA	5	1.5	8.4	5	1.5	6.5	5	0.3	5.1	6	0.5	4.5
a. (Ganglio)neuroblastoma	5	1.5	8.4	5	1.5	6.5	5	0.3	5.1	6	0.5	4.5
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.
V RETINOBLASTOMA	3	2.0	4.8	3	2.0	3.7	7	.	7.1	7	.	5.5
VI RENAL TUMOURS	6	1.0	9.4	6	1.0	7.3	8	1.0	7.8	9	0.8	6.7
a. Nephroblastoma	5	0.7	8.1	5	0.7	6.3	7	1.3	6.8	7	1.3	5.3
b. Renal carcinoma	1	.	1.2	1	.	0.9	1	0.0	1.0	2	0.0	1.4
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
VII HEPATIC TUMOURS	4	3.0	6.0	7	2.5	7.8	5	.	4.9	5	.	3.8
a. Hepatoblastoma	3	2.0	4.8	3	2.0	3.7	4	.	4.1	4	.	3.1
b. Hepatic carcinoma	1	.	1.2	4	3.0	4.1	1	.	0.9	1	.	0.7
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.
VIII BONE TUMOURS	7	.	9.9	8	7.0	8.7	7	1.3	5.4	8	1.0	4.8
a. Osteosarcoma	2	.	2.4	3	2.0	2.9	2	.	1.5	2	.	1.1
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	3	.	4.3	3	.	3.3	4	0.3	3.2	5	0.3	3.1
d. Other specified	1	.	1.4	1	.	1.1	1	.	0.7	1	.	0.6
e. Unspecified	1	.	1.7	1	.	1.3	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	5	0.7	8.1	12	1.0	13.6	7	0.4	5.7	14	1.0	8.6
a. Rhabdomyosarcoma	2	0.0	3.4	5	0.7	5.7	2	1.0	1.8	3	2.0	2.0
b. Fibrosarcoma	2	1.0	3.4	2	1.0	2.6	0	.	.	0	.	.
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	1	.	1.4	3	2.0	3.2	5	0.3	4.0	11	0.8	6.7
e. Unspecified	0	.	.	2	1.0	2.1	0	.	.	0	.	.
X GERM CELL TUMOURS	1	.	1.7	3	0.5	3.4	1	.	0.7	11	10.0	6.6
a. CNS germ cell	0	.	.	0	.	.	1	.	0.7	1	.	0.6
b. Other extragonadal	0	.	.	1	0.0	1.0	0	.	.	0	.	.
c. Gonadal germ cell	1	.	1.7	2	1.0	2.3	0	.	.	10	9.0	6.0
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	0	.	.	0	.	.
XI CARCINOMA & MELANOMA	3	.	3.9	15	0.5	15.5	8	1.0	6.4	18	0.6	11.0
a. Adrenocortical	1	.	1.2	1	.	0.9	0	.	.	0	.	.
b. Thyroid	2	.	2.6	9	0.8	9.3	2	1.0	1.5	5	0.3	2.9
c. Nasopharyngeal	0	.	.	1	0.0	1.0	1	0.0	0.7	1	0.0	0.6
d. Melanoma	0	.	.	0	.	.	2	0.0	1.7	3	0.0	1.9
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	0	.	.	4	0.0	4.2	3	.	2.5	9	2.0	5.5
XII OTHER & UNSPECIFIED	0	.	.	0	.	.	2	1.0	1.8	2	1.0	1.4
a. Other specified	0	.	.	0	.	.	0	.	.	0	.	.
b. Other unspecified	0	.	.	0	.	.	2	1.0	1.8	2	1.0	1.4
TOTAL	115	1.7	176.5	159	1.3	182.7	126	1.5	111.7	182	1.3	120.1

Please consult the quality indicators for the constituent registries